Compare COOK & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | SAVA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 157.0M |
| IPO Year | 2021 | N/A |
| Metric | COOK | SAVA |
|---|---|---|
| Price | $0.91 | $3.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $2.04 | ★ $5.00 |
| AVG Volume (30 Days) | 675.8K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $582,799,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.15 |
| 52 Week High | $3.31 | $4.98 |
| Indicator | COOK | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 52.90 |
| Support Level | $0.71 | $3.13 |
| Resistance Level | $0.84 | $3.38 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 60.08 | 75.15 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.